Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

13 slides

Aldeyra Therapeutics · Health & Biotech · 2022

About this deck

Explore the presentation slide by slide for its financial analysis, transaction details, and investor communications.

Read moreRead less
Company
Aldeyra Therapeutics
Industry
Health & Biotech
Year
2022
Slides
13
Company
Aldeyra Therapeutics
Industry
Health & Biotech
Year
2022
Slides
13
Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Investment Banking Pitch Deck | Banker Decks